Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

37.37USD
16 Jul 2018
Change (% chg)

-- (--)
Prev Close
$37.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
164,050
52-wk High
$44.26
52-wk Low
$16.51

Chart for

About

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being... (more)

Overall

Beta: --
Market Cap(Mil.): $1,153.38
Shares Outstanding(Mil.): 35.93
Dividend: --
Yield (%): --

Financials

BRIEF-Biohaven Initiates Expanded Access Program For Sublingual BHV-0223

May 9 Biohaven Pharmaceutical Holding Company Ltd:

09 May 2018

Biohaven plunges as investors pit migraine data against Allergan's drug

Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.

26 Mar 2018

Biohaven tumbles as migraine drug efficacy fails to impress investors

March 26 Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.

26 Mar 2018

BRIEF-Biohaven Pharmaceutical Q4 Loss Per Share $0.75

March 6 Biohaven Pharmaceutical Holding Company Ltd:

07 Mar 2018

BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​

March 6 Biohaven Pharmaceutical Holding Company Ltd:

06 Mar 2018

BRIEF-Biohaven Announces Positive Results With Sublingual Rimegepant Zydis Orally Dissolving Tablet

March 1 Biohaven Pharmaceutical Holding Company Ltd:

01 Mar 2018

Earnings vs. Estimates